X4 Pharma Secures EU Approval for First WHIM Syndrome Therapy with €226M Milestones
X4 Pharmaceuticals’ mavorixafor received European Commission marketing authorization for patients aged 12 and older with WHIM syndrome, marking the first approved treatment under exceptional circumstances in the EU. European commercialization by partner Norgine could trigger up to €226 million in milestones and mid-20s% royalties while a global Phase 3 4WARD trial in chronic neutropenia continues.
1. Company Achieves European Marketing Authorization
X4 Pharmaceuticals announced that the European Commission granted marketing authorization for XOLREMDI (mavorixafor) under exceptional circumstances to treat patients aged 12 years and older with WHIM syndrome. This approval establishes XOLREMDI as the first and only authorized therapy for the ultra-rare immunodeficiency disorder in the European Union.
2. Licensing Agreement and Milestone Payments
In January 2025 X4 entered into a licensing and supply agreement with Norgine covering Europe, Australia and New Zealand. Under the terms, X4 could receive up to €226 million in regulatory and commercial milestones plus escalating royalties in the mid-20s percent on future net sales in these territories.
3. Norgine’s Commercialization Plan
Norgine will assume all market access, distribution and promotional responsibilities following transfer of marketing authorizations. X4 will manufacture and supply mavorixafor, while Norgine implements patient access programs and prepares for launch across European markets.
4. Ongoing Global Phase 3 4WARD Trial
X4 is conducting the pivotal Phase 3 4WARD trial, a 52-week, randomized, double-blind, placebo-controlled study evaluating mavorixafor in chronic neutropenia. Positive results could support label expansion and additional regulatory filings in other neutropenic disorders.